Download
alzheimer disease assessment scale cognitive subscale adas cog 11 item n.
Skip this Video
Loading SlideShow in 5 Seconds..
Alzheimer Disease Assessment Scale—Cognitive Subscale (ADAS-cog) 11-Item PowerPoint Presentation
Download Presentation
Alzheimer Disease Assessment Scale—Cognitive Subscale (ADAS-cog) 11-Item

Alzheimer Disease Assessment Scale—Cognitive Subscale (ADAS-cog) 11-Item

4654 Views Download Presentation
Download Presentation

Alzheimer Disease Assessment Scale—Cognitive Subscale (ADAS-cog) 11-Item

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Alzheimer Disease Assessment Scale—Cognitive Subscale (ADAS-cog) 11-Item Increasing scores indicate worsening cognitive function.Rosen WG, et al. Am J Psychiatry. 1984;141:1356-1364.

  2. Treatment Difference at Wk 24 on ADAS-cog by CountryCore Study—ITT+RDO Population Austria (N = 9) Belgium (N = 21) Canada (N = 41) Germany (N = 63) Spain (N = 59) France (N = 63) Great Britain (N = 48) Italy (N = 118) Netherlands (N = 18) –39.67 46.92 Norway (N = 7) –29.92 Portugal (N = 9) Turkey (N = 45) –20 –10 0 10 20 Favor placebo Favor Exelon LS mean difference (95% CI).

  3. Duration of Nausea and Vomiting and Number of Events per PatientCore Study † Events with no end dates recorded, which may or may not have resolvedby last study visit.

  4. Duration of Tremor and Number of These Events per PatientCore Study 1 episode: 34 patients; 2 episodes: 3 patients. † Events with no end dates recorded, which may or may not have resolved by last study visit.

  5. AE of Tremor Over TimeCore and Extension Studies Patients are counted more than once if event continues through multiple periods.

  6. Change on ADAS-cog Sub-items at Wk 24Core Study—OC Population *p < 0.05 † p value based on van Elteren test blocking for country.

  7. Major Protocol ViolationsCore Study

  8. Dopaminergic Agents—Dose Increase After Start of Study DrugCore Study Doses were required to remain unchanged unless clinically indicated.